1.51 0.00 (0.00%)
After hours: 6:51PM EST
|Bid||1.52 x 1400|
|Ask||1.55 x 800|
|Day's Range||1.49 - 1.60|
|52 Week Range||1.46 - 6.99|
|Beta (3Y Monthly)||2.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Alexis Christoforous to discuss the latest market moves as Wall Street digests headlines about US-China trade relations, this morning's BLS Employment Situation report, and a barrage of earnings, from Apple to Exxon Mobil. Here's the performance of recent earnings (as of 10:45 am EDT, Friday): ~Thurs AMC SBUX Starbucks Corp 10.60% SYMC(E) Symantec Corp 6.43% MET Metlife Inc 4.41% X U.S. Steel Corporation 2.54% WU Western Union Co (THE) -0.25% CBS CBS Corporation -1.25% EOG EOG Resources -2.25% AAPL Apple Inc -6.72% KHC The Kraft Heinz Company -7.82% GERN(HB) Geron Corp -8.11% SHAK Shake Shack Inc -11.41% GPRO GoPro Inc Cl A -21.80% OLED Universal Display Corp -27.13% WTW Weight Watchers Intl -29.87% ~Fri BMO CVX Chevron Corporation 3.48% STX(HB) Seagate Tech 2.78% IMGN Immunogen Inc 2.69% ABBV AbbVie Inc 2.48% XOM Exxon Mobil 1.41% DUK Duke Energy Corporation 0.58% BABA Alibaba Group Holding Ltd -0.84% CBOE CBOE Glbl Mkts Inc -1.23%
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...
MENLO PARK, Calif., Nov. 07, 2018 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to.
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Geron (GERN) delivered earnings and revenue surprises of 40.00% and -25.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had a loss of 3 cents per share. The drugmaker posted revenue of $165,000 in the period. The company's shares closed at $1.85. A year ago, they were trading ...
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American.
MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced that clinical data related to imetelstat, the Company’s first-in-class telomerase inhibitor, will be the subject of two oral presentations at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California from December 1-4, 2018. The abstracts, summarizing clinical data from Part 1 of IMerge in myelodysplastic syndromes and the IMbark primary analysis in myelofibrosis, were published today on the ASH website at www.hematology.org.
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...
Geron Corporation (GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018. Geron will host a conference call to discuss the third quarter results and recent events at 4:30 p.m. ET the same day. Geron is a clinical stage biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included leaders in e-commerce, smartphones and footwear. Bearish calls included a struggling conglomerate ...